AP505F
Goat Anti-Human Ig κ chain Antibody, FITC conjugate
Chemicon®, from goat
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
biological source
goat
Quality Level
conjugate
FITC conjugate
antibody form
affinity purified immunoglobulin
antibody product type
secondary antibodies
clone
polyclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
immunofluorescence: suitable
shipped in
wet ice
target post-translational modification
unmodified
Categorías relacionadas
General description
Antibody molecules typically comprise two immunoglobulin light chains covalently bound to a pair of heavy chains. Immunoglobulin light chains occur in two types, designated by the Greek letters kappa and lambda. Kappa and lambda light chains are approximately 250 amino acids in length with an average mass of about 25 kDa. The ratio of kappa to lambda found in the immunoglobulin population varies by species.
Specificity
Reacts with human kappa light chains. Absorbed for human myeloma proteins with λ light chains.
Application
Immunofluorescence: ≤1 μg/106 cells.
Optimal working dilutions must be determined by the end user.
Optimal working dilutions must be determined by the end user.
This Goat anti-Human Ig κ chain Antibody, FITC conjugate is validated for use in IF for the detection of Human Ig κ chain.
Physical form
Purified by affinity chromatography on pooled human Igs with kappa light chains covalently linked to agarose. Liquid in 1.0 mL PBS/NaN3.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
¿No encuentra el producto adecuado?
Pruebe nuestro Herramienta de selección de productos.
Storage Class
10 - Combustible liquids
wgk_germany
WGK 2
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Joel G Turner et al.
Oncotarget, 7(48), 78896-78909 (2016-11-03)
Acquired proteasome-inhibitor (PI) resistance is a major obstacle in the treatment of multiple myeloma (MM). We investigated whether the clinical XPO1-inhibitor selinexor, when combined with bortezomib or carfilzomib, could overcome acquired resistance in MM. PI-resistant myeloma cell lines both in
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico